Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E -Mutated Anaplastic Thyroid Carcinoma
Authors' conclusion
Our results show that in BRAFm-ATC, addition of pembrolizumab to dabrafenib/trametinib may significantly prolong survival. Surgical resection of the primary tumor after initial BRAF-targeted therapy in selected patients may provide further survival benefit. However, conclusions are limited by the retrospective nature of the study.
Study context
- Population
- Patients with BRAFV600E-mutated anaplastic thyroid carcinoma (BRAFm-ATC) treated with first-line BRAF-directed therapy, January 2014–March 202371 in primary analysis
- Participants
- 48 / 23 / 23
- Exposure
- DT plus pembrolizumab vs DT alone
- DTPn = 48
- DTn = 23reference
- Neoadjuvantn = 23
- Outcome
- Median overall survival (mOS) between DT and DTP
Methodological detailssingle-center
- Single-center
Main finding
As reported in the abstract
Median overall survival
P = 0.037
Observational data: associations, not effects.
Secondary outcomes
Median, months
| Outcome | DTP | DT | P value |
|---|---|---|---|
| Median PFS (initial treatment)DTP vs DT · significantly improved with DTP | 11.0 (CI 7.0–15.0) | 4.0 (CI 0.7–7.3) | P = 0.049 |
- Median OS, neoadjuvant (exploratory)
- 63.0 · median · CI 15.5–110.5 · months
Safety
- Immune-related adverse events (AEs), most frequently hepatitis and colitis
- 32.4%
- No grade 5 AEs occurred in all three cohorts
Original publication
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E -Mutated Anaplastic Thyroid Carcinoma. Thyroid. Published 16 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →